Drug overpricing: Govt plans amnesty scheme to recover dues from pharma companies

In a bid to tackle overpricing in the pharmaceutical sector, the government is planning an amnesty scheme to recover dues from pharmaceutical companies, CNBC Aawaz reported.

The National Pharmaceutical Pricing Authority (NPPA), responsible for overseeing drug pricing, has identified a substantial 2,200 cases of overpricing within the pharmaceutical industry.

Among the companies under scrutiny for overpricing practices are well-known names such as Cipla, Sun Pharma, and Lupin. These cases collectively involve dues amounting to approximately Rs. 13,000 crore.

The amnesty scheme proposes relief for pharmaceutical companies, offering waivers on interest and penalties associated with the alleged overpricing issues.

Pharma makers get a year for GMP implementation, Mandaviya warns action on defaults

The primary objective of the amnesty scheme is to recover outstanding dues from these companies. It is estimated that the government aims to retrieve around Rs. 5,000 to 6,000 crore through this initiative.

How are drug prices regulated?

Periodically, the Health Ministry collaborates with experts to create the National List of Essential Medicines (NLEM). This list includes medications vital for treating prevalent conditions and falls under price control through the Drug Price Control Order (DPCO).

The NPPA, a part of the Indian Government, was established to regulate drug prices. It enforces pricing and availability of medicines as per the Drugs (Prices Control) Order, 1995. NPPA also recovers overcharged amounts from consumers and monitors prices of unregulated drugs to ensure affordability.

Related Posts

  • Pharma
  • September 7, 2024
  • 123 views
Haryana-Based Drug Dist. Arrested For Supplying Prescription Drugs To Coimbatore Peddlers

Coimbatore: A special team of the Coimbatore City Police has arrested a Haryana-based drug distributor on charges of supplying prescription drugs to peddlers in Coimbatore. The police said that Sachin Garg,…

  • Pharma
  • September 7, 2024
  • 100 views
Inappropriate Use Of ‘Sulopenem’ Could Cause Antimicrobial Resistance (AMR)

Maryland: Five months after signing off on Utility Therapeutics’ Pivya as the first new treatment for uncomplicated urinary tract infections (uUTIs) in more than two decades, the FDA is weighing the pros and…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Haryana-Based Drug Dist. Arrested For Supplying Prescription Drugs To Coimbatore Peddlers

Haryana-Based Drug Dist. Arrested For Supplying Prescription Drugs To Coimbatore Peddlers

People with Spinal Injuries are left to fend for themselves in India

People with Spinal Injuries are left to fend for themselves in India

Inappropriate Use Of ‘Sulopenem’ Could Cause Antimicrobial Resistance (AMR)

Inappropriate Use Of ‘Sulopenem’ Could Cause Antimicrobial Resistance (AMR)

Medical Shop Owner Faces Charges For Drug Money Laundering In Punjab

Medical Shop Owner Faces Charges For Drug Money Laundering In Punjab

Narayana Health is poised to transform Nurses Skills to enhance Patient Outcomes

Narayana Health is poised to transform Nurses Skills to enhance Patient Outcomes

DCGI Seeks Explanation From Entod Pharma Claiming Eye Drops Can Cure Eyesight

DCGI Seeks Explanation From Entod Pharma Claiming Eye Drops Can Cure Eyesight